Michael Baria: Is PRP Disease Modifying in Osteoarthritis?
Michael Baria, Lead for The Early Osteoarthritis and Joint Health Program at The Ohio State University Wexner Medical Center, Head Team Physician for Ohio State Wrestling at The Ohio State University Department of Athletics, shared a post on LinkedIn about a recent article by Jiabao Chu et al. published in KSSTA:
“Here is a study I don’t think has gotten nearly enough attention.
Chu et al randomized over 600 knee OA patients (that alone is a feat) to receive either 3, weekly LP-PRP (4 fold platelets) or saline placebo.
Beyond the usual symptom improvement, the imaging results are impressive.
At 5 years, the PRP group lost cartilage volume at half the rate compared to saline.
A single round of PRP reduced cartilage loss for 5 years.
Amazing.
Whereas 10 years ago, the party line was that PRP is still only modifying symptoms, we can put to bed the question ‘is PRP disease modifying?‘.
We have clear evidence it is.
More encouraging; this was disease modifying with only 1 round of treatment.
Most of our patients routinely seek care every 6-12 months so we have every expectation their outcomes are even better.”
Title: Intra-articular injections of platelet-rich plasma decrease pain and improve functional outcomes than sham saline in patients with knee osteoarthritis
Authors: Jiabao Chu, Weifeng Duan, Ziqiang Yu, Tao Tao, Jie Xu, Qianli Ma, Lingying Zhao, Jiong Jiong Guo
Read the Full Article on KSSTA
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 11:14Yohan Santin: How Lysosomal Dysfunction Drives Cardiac Aging
-
Aug 14, 2026, 11:06Nicolas Schommer: When Neutrophils Turn Metabolic Stress Into Organ Injury
-
Aug 14, 2026, 10:49Pablo Corral: Can One Infusion Lower LDL for Years
-
Aug 14, 2026, 08:17Maha Othman: Celebrating Research and Collaboration at the Sinclair Cancer Research Institute 2026 Annual Retreat
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed